Literature DB >> 11696729

Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.

T A Stamey1, J A Warrington, M C Caldwell, Z Chen, Z Fan, M Mahadevappa, J E McNeal, R Nolley, Z Zhang.   

Abstract

PURPOSE: Because Gleason grade 4/5 cancer is the primary cause of failure to cure prostate cancer, we examined the molecular profiles of this high grade cancer in search of potentially new therapeutic interventions as well as better serum markers than prostate specific antigen.
MATERIALS AND METHODS: We compared the gene expressions in fresh frozen tissues from 9 men with Gleason grade 4/5 cancer to 8 men with benign prostatic hyperplasia (BPH) treated with radical retropubic prostatectomy. Labeled complementary RNA from each of the 17 tissues was applied to HuGeneFL probe arrays representing approximately 6,800 genes (Affymetrix, Inc., Santa Clara, California). After removing all genes undetectable in BPH and grade 4/5 cancers, and transforming the data into a parametric distribution, we chose only those up and down-regulated genes with a p difference in fluorescence between grade 4/5 cancer and BPH of p <0.0005. This value reduced the data set to 40 up-regulated and 111 down-regulated genes. We then eliminated all genes that were not expressed in all 8 BPH and 9 grade 4/5 tissues, which produced a final set of 86 genes, of which 22 were up-regulated and 64 were down-regulated.
RESULTS: Cluster analysis cleanly separated men with grade 4/5 cancers from those with BPH. Only 17 of the 86 candidate genes (20%) were known to be prostate cancer related and 42 (49%) were related to other cancers. The most up-regulated gene is Hepsin, a trypsin-like serine protease with its enzyme catalytic domain oriented extracellularly. Prostate specific membrane antigen is the second most up-regulated gene (all other reports on prostate specific membrane antigen have been at the protein level). The genes for prostate specific antigen (hK3) and human glandular kallikrein2 (hK2) showed equivalent expression levels 10 times the average of other genes. Complete lists of all 22 up-regulated genes and 64 down-regulated genes, together with their locus on the chromosome, are presented in rank order.
CONCLUSIONS: We characterize for the first time 64 down-regulated and 22 up-regulated genes in Gleason grade 4/5 cancer, using the gene profile from BPH as control tissue. A number of interesting new genes, previously undescribed in prostate cancer, are presented as possibilities for further study.

Entities:  

Mesh:

Year:  2001        PMID: 11696729

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  43 in total

Review 1.  Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.

Authors:  Peter Sazani; Ryszard Kole
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

2.  Identification of Marker Genes for Cancer Based on Microarrays Using a Computational Biology Approach.

Authors:  Xiaosheng Wang
Journal:  Curr Bioinform       Date:  2014-04-01       Impact factor: 3.543

3.  Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer.

Authors:  Milly J McAllister; Pamela McCall; Ashley Dickson; Mark A Underwood; Ditte Andersen; Elizabeth Holmes; Elke Markert; Hing Y Leung; Joanne Edwards
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-01       Impact factor: 5.554

4.  Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers.

Authors:  Zuxiong Chen; Zulfiqar G Gulzar; Catherine A St Hill; Bruce Walcheck; James D Brooks
Journal:  Prostate       Date:  2014-05-22       Impact factor: 4.104

5.  The L1-version of the Cramér-von Mises test for two-sample comparisons in microarray data analysis.

Authors:  Yuanhui Xiao; Alexander Gordon; Andrei Yakovlev
Journal:  EURASIP J Bioinform Syst Biol       Date:  2006

6.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

7.  Identification and characterization of small-molecule inhibitors of hepsin.

Authors:  John R Chevillet; Gemma J Park; Antonio Bedalov; Julian A Simon; Valeri I Vasioukhin
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

8.  Accurate molecular classification of cancer using simple rules.

Authors:  Xiaosheng Wang; Osamu Gotoh
Journal:  BMC Med Genomics       Date:  2009-10-30       Impact factor: 3.063

9.  LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.

Authors:  Tammy L Romanuik; Gang Wang; Olena Morozova; Allen Delaney; Marco A Marra; Marianne D Sadar
Journal:  BMC Med Genomics       Date:  2010-09-24       Impact factor: 3.063

10.  Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Authors:  Srinivas Nandana; Katharine Ellwood-Yen; Charles Sawyers; Marcia Wills; Brandy Weidow; Thomas Case; Valeri Vasioukhin; Robert Matusik
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.